The three-part Phase 1/2 study (NCT06265727) is evaluating the safety, pharmacokinetics and efficacy of CRB- 701 in participants with advanced solid tumors associated with high Nectin-4 expression. The Part A dose escalation of the study evaluated four predetermined doses (1.8 mg/kg, 2.7 mg/kg, 3.6 mg/kg and 4.5 mg/kg Q3W) and is being followed by Part B (dose optimization) and Part C (dose expansion). Dose optimization is on-going with dosing at 2.7 mg/kg and 3.6 mg/kg cohorts in HNSCC, cervical and mUC tu ...